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Abstract
Background
Glucosamine and chondroitin are popular non-vitamin dietary supplements used for osteo-
arthritis. Long-term use is associated with lower incidence of colorectal and lung cancers
and with lower mortality; however, the mechanism underlying these observations is un-
known. In vitro and animal studies show that glucosamine and chondroitin inhibit NF-kB, a
central mediator of inflammation, but no definitive trials have been done in healthy humans.
Methods
We conducted a randomized, double-blind, placebo-controlled, cross-over study to assess
the effects of glucosamine hydrochloride (1500 mg/d) plus chondroitin sulfate (1200 mg/d)
for 28 days compared to placebo in 18 (9 men, 9 women) healthy, overweight (body mass
index 25.0–32.5 kg/m2) adults, aged 20–55 y. We examined 4 serum inflammatory biomark-
ers: C-reactive protein (CRP), interleukin 6, and soluble tumor necrosis factor receptors
I and II; a urinary inflammation biomarker: prostaglandin E2-metabolite; and a urinary oxida-
tive stress biomarker: F2-isoprostane. Plasma proteomics on an antibody array was per-
formed to explore other pathways modulated by glucosamine and chondroitin.
Results
Serum CRP concentrations were 23% lower after glucosamine and chondroitin compared
to placebo (P = 0.048). There were no significant differences in other biomarkers. In the pro-
teomics analyses, several pathways were significantly different between the interventions
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after Bonferroni correction, the most significant being a reduction in the “cytokine activity”
pathway (P = 2.6 x 10-16), after glucosamine and chondroitin compared to placebo.
Conclusion
Glucosamine and chondroitin supplementation may lower systemic inflammation and alter
other pathways in healthy, overweight individuals. This study adds evidence for potential
mechanisms supporting epidemiologic findings that glucosamine and chondroitin are asso-
ciated with reduced risk of lung and colorectal cancer.
Trial Registration
ClinicalTrials.gov NCT01682694
Introduction
Glucosamine and chondroitin (G&C), often taken together as a single pill and used for osteoar-
thritis, are among the most popular dietary supplements in the US [1]. G&C are considered
safe, with no known major adverse side effects [2]. While the efficacy of these supplements for
treatment of osteoarthritis remains debated [2,3], recent studies suggest that they may have po-
tential for reducing risk of other chronic diseases, such as cancer. In the VITamins And Life-
style (VITAL) study, a large (n = 77,738) prospective cohort, we reported that use of G&C
supplements is associated with a 27–35% lower incidence of colorectal cancer [4], a 26–28%
lower incidence of lung cancer [4], 17% lower overall mortality [5], and a 13% lower cancer
mortality [6]. These findings on G&C were the most consistent results across endpoints among
the 30 supplements that were the focus of the VITAL study.
It is generally well-accepted that chronic inflammation contributes to carcinogenesis [7].
The majority of cellular events involved in the inflammation process require nuclear factor
kappa B (NK-κB), a transcription factor that plays a central role in the generation of cytokines,
chemokines and other soluble factors involved in the immune response. Similarly, excess reac-
tive species characteristic of oxidative stress can damage cell membranes and DNA [8], and are
thought to contribute to genomic instability and development of cancer [9]. Several lines of
compelling evidence from in vitro and preclinical studies support a possible role for G&C in re-
ducing inflammation [10–13]. A limited number of human observational and randomized
studies also suggest that G&C lower systemic biomarkers of inflammation and oxidative stress
[14,15]; however, no human intervention trials have evaluated the potential for G&C to reduce
inflammation or alter other pathways relevant to carcinogenesis in healthy individuals free of
chronic inflammatory conditions.
Our objectives in the present study were two-fold. Our first aim was to determine the effect
of a common dose of G&C on a panel of serum inflammation biomarkers [high sensitivity
C-reactive protein (CRP), interleukin-6 (IL-6), and soluble tumor necrosis factor receptors
I & II (sTNFRI and II); a urinary biomarker of inflammation, prostaglandin E2-metabolite
(PGE-M); and a urinary biomarker of oxidative stress, F2-isoprostane (F2-IsoP)]. Secondly, we
sought to characterize intervention-induced changes in plasma proteomic patterns via pathway
analyses in response to G&C compared to placebo. Results from this study may help determine
the anti-inflammatory potential of G&C in humans, and may identify other possible pathways
that may be modulated with use of G&C.
Glucosamine and Chondroitin and Inflammation
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Methods
Research Design
The study was a randomized, double-blind, placebo-controlled, crossover trial comparing sup-
plemental glucosamine and chondroitin to placebo. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see S1 Protocol and S1 CON-
SORT Checklist. As this was a small pilot trial with the aim of enrolling a sample of 20 individ-
uals, participants were randomly assigned by the project manager to begin with either the
active or placebo intervention period in blocks of two using a pre-determined randomization
template alternating placebo and G&C interventions. Each new recruit was assigned to the
next available assignment. Each intervention period lasted 28 days with a 28 day washout peri-
od between the two interventions. All study activities were carried out at the Fred Hutchinson
Cancer Research Center (FHCRC), Seattle, Washington. Recruitment, enrollment, trial, and
sample collection took place from October 2012 to July 2013. The study protocol was approved
by the FHCRC Institutional Review Board on July 11, 2012, with continuation approval ob-
tained through May 18, 2015. All participants gave informed written consent. The authors con-
firm that all ongoing and related trials for this intervention are registered. This trial was
registered at http://www.clinicaltrials.gov as NCT01682694.
Participants
Participants were healthy, overweight [BMI (body mass index)>25 and32.5 kg/m2], non-
smoking, aged 20–55 years, and recruited from the greater Seattle area. We recruited men and
women who were overweight because inflammation biomarkers are unlikely to decrease
measurably in response to an intervention among individuals who have very low systemic in-
flammation at baseline, and BMI is a strong predictor of both CRP and IL-6 [16,17]. Methods
for recruitment included flyers posted on university campuses in Seattle and at FHCRC, an in-
formational website, and advertisements in campus and local neighborhood newspapers.
Screening occurred in two phases. In the first phase, individuals were screened for eligibility
using a self-administered questionnaire and were excluded for any of the following: chronic
medical illness; history of gastrointestinal, hepatic, or renal disorders; inflammatory conditions
(including autoimmune and inflammatory diseases); pregnancy or lactation; currently on a
weight loss diet; BMI<25 or32.5 kg/m2; alcohol intake>2 drinks/day (2 drinks defined as
720 ml beer, 240 ml wine or 90 ml spirits); current use of prescription or over-the-counter
medications other than oral contraceptives and hormone-secreting IUDs, multivitamins or use
of aspirin or NSAIDs more than 2 days per week; inability to swallow pills; known allergy to
shellfish; not willing to take pills made from shellfish or animal sources; or intention to relocate
out of the study area within the next 4 months. Eligible individuals were invited to a study in-
formation session and those interested in participating provided informed written consent.
In the second phase of screening, prospective participants attended a screening clinic visit at
the FHCRC Prevention Center. Height and weight were measured to ensure BMI requirements
were met. Because body fat can vary among similar BMIs, body fat percentage was assessed by
whole-body dual-energy X-ray absorptiometry (DEXA) scanning using a GE Lunar DPX-Pro
densitometer (GE Healthcare, Milwaukee, WI). Blood was drawn in the morning after an over-
night fast and was used for analysis of renal (blood urea nitrogen: 7–25 mg/dl; creatinine:
0.50–1.10 mg/dl for females; 0.60–1.35 mg/dl for males; eGFR 60 ml/min/1.73m2; sodium:
135–146 μmol/l; potassium: 3.5–5.3 μmol/l; chloride: 98–110 μmol/l), liver (albumin: 3.6–5.1
g/dl; globulin: 2.1–3.7; total bilirubin: 0.2–1.2 mg/dl; alkaline phosphatase: 40–115 U/L; AST:
10–30 U/L for females; 10–40 U/L for males; ALT: 6–40 U/L for females; 9–60 U/L for males),
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PLOS ONE | DOI:10.1371/journal.pone.0117534 February 26, 2015 3 / 20
and metabolic function (glucose: 65–99 mg/dl). Individuals with normal laboratory values
were invited to participate in the study.
A total of 27 individuals underwent screening activities. Seven were ineligible prior to ran-
domization, six due to high fasting glucose concentrations and one due to abnormal liver en-
zyme concentrations. Twenty individuals (n = 10 men; n = 10 women) were randomized. One
female was asked to drop out after completing only one intervention period because she started
a new diet and exercise program that might have had effects on biomarker measures. Because
inflammation biomarkers are influenced by minor infections (e.g., colds) and other illnesses
[18], participants were instructed to delay clinic visits until they were no longer ill; however,
one male participant attended a clinic visit at the onset of a cold and was also excluded, leaving
a sample size of 18 (9 men and 9 women; Fig. 1).
Glucosamine and Chondroitin Supplements
Our aim was to evaluate G&C as used in population settings. Thus, dosing was based on the
common starting dose recommended by the product manufacturer, which is similar across
G&C products. The active treatment was 1500 mg/d FCHG49 glucosamine hydrochloride
(GHCl) + 1200 mg/d TRH122 sodium chondroitin sulfate (CS) taken as 3 capsules daily with
Fig 1. CONSORT Flow diagram of participants in the glucosamine and chondroitin (G&C) randomized, placebo-controlled trial.
doi:10.1371/journal.pone.0117534.g001
Glucosamine and Chondroitin and Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0117534 February 26, 2015 4 / 20
each capsule containing 500 mg GHCl and 400 CS. Crystalline cellulose was used as an inactive
filler, and both active treatment and placebo were encapsulated in clear gelatin capsules. The
placebo was similar in appearance and contained only the inactive filler. Both G&C and the
placebo were generated from a single lot of source materials and donated by Nutramax Labora-
tories Consumer Care, Inc. (Edgewood, MD). Supplement bottles were provided by the
manufacturer with a single printed label containing the letters “A” or “B”. To maintain double-
blinding for both participants and investigators, the randomization algorithm was sent in a
sealed envelope to an investigator uninvolved in the day to day study activities; unblinding of
the interventions was done at the time of data analysis. Participants were contacted by study
staff at the mid-point and end of each intervention period to assess any possible adverse experi-
ences and compliance. No adverse events were reported. Extra pills were included in each sup-
plement bottle in the event that a Day 28 study visit was delayed, and so that adherence
percentages (pills supplied—pills returned/days elapsed) could be calculated as an additional
compliance measure. Composition of analysis testing was performed by an independent labo-
ratory (Tampa Bay Analytical Research, Inc., Clearwater, FL) in collaboration with the NIH
Office of Dietary Supplements. HPLC-UV analysis of a subset of capsules confirmed that mean
G&C content was within specifications. No G&C was detected in the placebo capsules and no
microbial products were detected in either capsule type.
Specimen Collection
Biological samples were collected at baseline (screening visit) and after each 28-day interven-
tion period in the morning after a minimum of a 12-hour overnight fast. For blood samples,
tubes without additive were allowed to clot at room temperature for 30 minutes before they
were centrifuged to separate the serum. Blood was also drawn into a tube containing EDTA for
plasma. Both serum and plasma were aliquoted and stored at -80°C.
Participants were given a urine collection kit and instructions before each visit, and brought
the specimen with them to the clinic visit. Participants were instructed to collect all of their
urine for the 12 hours prior to their morning clinic visit at baseline and on Day 28 of each in-
tervention period. Urine-void times were recorded and any uncollected voids noted. Urine
specimens were stored at 4°C until delivery to the FHCRC the morning following collection.
Urine volume was measured and aliquots stored at 80°C.
Laboratory Analyses
Serum Inflammation Biomarkers. All assays were performed on never-thawed samples
with the exception of CRP which is stable through freeze-thaw cycles, and was measured in
samples that had been thawed once [19]. No observations were below the limit of detection for
any markers. Assays for all inflammation markers have been described [20]. Intra and inter-
assay CVs for CRP, IL-6, and sTNFRI and II were 1.7% and 5.5%; 3.7% and 5.8%; 2.1% and
1.7%; and 2.3% and 5.6%, respectively.
Urinary Inflammation and Oxidative Stress Biomarkers. Urinary PGE-M (11-alpha-
hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid), the stable metabolite of PGE2,
was assayed at the Vanderbilt Eicosanoid Core Laboratory (VECL, Nashville, TN) by a liquid
chromatography/mass spectrometry (LC/MS) method, as previously described [21]. Urinary
F2-IsoP was measured by gas-chromatography (GC)-negative-ion chemical ionization MS by
the VECL using an Agilent 5973 GC/MS system (Santa Clara, CA) [22].
Proteomics Analysis of Plasma. Plasma samples were evaluated on a customized anti-
body array populated with ~3,000 full-length antibodies, printed in triplicate on a single micro-
array [23–25]. Briefly, to analyze proteins in the plasma samples, we depleted albumin and
Glucosamine and Chondroitin and Inflammation
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IgG. Protein (200 μg) from the two participant blood draws were each labeled with Cy5. Each
sample was combined with reference sample and pipetted at the microarray/coverslip junction
followed by incubation for 90 min at room temperature in the dark. Unbound proteins were re-
moved by washing and the slides scanned for Cy3 and Cy5 fluorescence in an Axon Genepix
4000B scanner. The Cy5/Cy3 ratio determined the relative concentration of protein compared
to reference. The array contains antibodies to cytokines (e.g., interleukins 1A, 1B, 2, 3, 4, 4R, 5,
6, 7, 8, 10, 12A, 13, 15, 16, 17D, 18, 19, 20, 24, 28A, and 34 and interleukin receptors 2RA, 2RA,
3RA, 4R, 5RA, 6ST, 17RA and 17RB), adipokines, proteins involved in apoptosis, angiogenesis,
T-cell activation/infiltration, inflammation/prostaglandins, insulin, insulin resistance toll-like
receptor (TLR), transforming growth factor (TGF)-β, and STAT signaling pathways that have
been reported to be deregulated in a variety of diseases. Most (>85%) antibodies on the array
had coefficients of variation, for triplicates, of less than 10% [23,24,26,27]. Detailed protocol
descriptions of array fabrication, plasma treatment, plasma labeling, incubation, and scanning
have been published elsewhere [23,27].
Array Analysis and Normalization
Array data contain a format identical to two-channel gene expression arrays and analysis pro-
ceeds analogously. The array image was scanned using a GenePix 4000B (Axon Instruments)
scanner. The numerical data processed by Genepix Pro 6.0 were imported to Limma 2.4.11
(Linear Models for Micro Array, a Bioconductor R package [28]). For each antibody, fold-
change of the signal (red channel) was compared to the reference (green channel). The M value
was calculated as Red/Green, where Red and Green were computed after background correc-
tion using the “normexp”method [29]. Saturated array spots were flagged and triplicate anti-
bodies with coefficients of variation>10% were removed. Experimental variation was
normalized using within-array print-tip loess and between-array quartile normalization. Trip-
licate features were summarized using their median. M values were standardized such that the
mean value and standard deviation of the placebo group was set to zero and one, respectively.
After all processing, data were available for analysis on a total of 2938 antibodies.
Statistical Analysis
All inflammatory and oxidative stress biomarkers were log-transformed to improve the nor-
mality of the distributions prior to analysis. Results are presented as geometric means with
95% confidence intervals (CI). Generalized estimating equations (GEE), which account for cor-
relation of repeated measures, were used to assess the effects of G&C versus placebo on inflam-
mation and oxidative stress. Analysis of each Day 28 inflammatory or oxidative stress
biomarker was adjusted for the same biomarker concentration at Day 0 for each treatment pe-
riod. Sex, age, and body-fat percent were selected a priori as additional covariates for adjust-
ment in the model. We also evaluated the effect of treatment period but because it did not
affect the point estimates, (i.e., carryover effects were not contributing to outcome measures),
we did not include treatment period in the models. The two-sided P value for statistical signifi-
cance for biomarkers of inflammation and oxidative stress was set at<0.05. Analyses were per-
formed using Stata statistical software (v13.1, StataCorp, College Station, TX).
Proteomics data were analyzed by performing paired t-tests to determine statistically signifi-
cant differences between the two interventions, after adjusting for covariate effects, including
hybridization day, and plate and box position by linear regression. Antibody markers were
ranked on the basis of p value and effect sizes, so that a positive value indicates that the anti-
body expression was greater after supplementation with G&C compared to placebo, and a neg-
ative value indicates lower expression. To further integrate the antibody at the protein level,
Glucosamine and Chondroitin and Inflammation
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multiple duplicated antibodies for the same protein that did not have at least two significant re-
sults with the effect size going in the same direction were excluded. Among those proteins with
at least two concordant significant results, the most significant antibody was reported for the
top 100 proteins. Gene Set Enrichment Analyses, the evaluation of microarray data at the level
of “gene groups” that share a common biologic theme or cellular location, were carried out
based on the t-test results using Kyoto Encyclopedia of Genes and Genomes (KEGG) [30] and
the gene set database Gene Ontology (GO) [31] downloaded from the Molecular Signatures
Database (MSigDB, http://www.broadinstitute.org/gsea/msigdb/index.jsp). We used a Bonfer-
roni correction to determine significant differences within the KEGG pathway [P<3.85x10-4;
(0.05/130, the total number of pathways evaluated in KEGG)], the GO pathway [P<5.18x10-5;
(e.g., 0.05/966, the total number of pathways evaluated in GO)], and for the individual proteins
[P<1.70x10-5; (0.05/2,938, the total number of antibodies on the array)].
Results
Table 1 summarizes the demographic and baseline characteristics of the 18 study participants
stratified by sex. Baseline measures of all inflammatory biomarkers were higher among men,
while F2-isoP was lower.
Statistically significantly lower geometric mean CRP concentrations were observed after the
G&C intervention compared to placebo (-23%, P = 0.048; Table 2). No significant differences
were observed in the other inflammation or oxidative stress biomarkers assessed, although they
were slightly lower after G&C supplementation with the exception of the soluble TNF recep-
tors, which increased by 1–3%.
Of the ~3,000 antibodies on the proteomics array, 2,938 were detected. We conducted gene-
set enrichment pathway analyses using both KEGG and GO database tools (Table 3). Five
pathways in the KEGG pathway analysis remained statistically significant after a Bonferroni
correction (nominal p-values 7 x 10-10 to 4 x 10-5)—cytokine-cytokine receptor interaction,
JAK/STAT signaling pathway, intestinal immune network for IGA production, leukocyte
transendothelial migration, and ubiquitin-mediated proteolysis. Twenty-five pathways in the
Table 1. Characteristics of participants randomized in the crossover trial of glucosamine and
chondroitin at baseline (n = 18).
Men (n = 9) Women (n = 9)
Personal characteristics1
Age (y) 40 (8.0) 38 (8.8)
BMI (kg/m2) 27 (2.8) 29 (2.4)
Body fat (%)2 32 (4.6) 39 (4.1)
Inﬂammation biomarkers3
CRP mg/l 1.18 (1.3) 0.77 (1.1)
IL-6 pg/ml 1.19 (0.9) 0.52 (0.2)
sTNFRI pg/ml 1119 (287) 654 (398)
sTNFRII pg/ml 5832 (1280) 5398 (620)
PGE-M (ng/mg creatinine) 8.32 (4.7) 3.83 (1.3)
F2-isoprostane (ng/mg creatinine) 1.00 (0.4) 1.13 (0.4)
1Mean (SD)
2Measured by Dual X-ray Absorptiometry (DEXA)
3Geometric mean (geometric SD)
doi:10.1371/journal.pone.0117534.t001
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GO pathway analyses remained statistically significant after Bonferroni correction (p values
3 x 10-16 to 1 x 10-5), including cytokine activity, receptor binding, hematopoietin/interferon
(classD 200 domain) cytokine receptor binding, growth factor activity, extracellular region,
chemokine activity, extracellular space, G-protein coupled receptor binding, chemokine recep-
tor binding, extracellular region part, locomotory behavior, membrane fraction, response to ex-
ternal stimulus, regulation of actin filament length, regulation of actin polymerization and/or
depolymerization, regulation of cellular component size, behavior, actin polymerization and/or
depolymerization, regulation of organelle organization and biogenesis, regulation of cytoskele-
ton organization and biogenesis, response to biotic stimulus, nucleus, microtubule-based pro-
cess, response to other organism and cell fraction. In each analysis, cytokine activity/cytokine
receptor binding was the most significantly affected pathway. With the exception of ubiquitin-
mediated proteolysis, and proteins located in the nucleus, all pathways were down-regulated
after G&C supplementation.
Of the individual proteins, 508 were statistically significantly different between the two in-
terventions with a Bonferroni correction (p< 1.7 x 10-5). The 100 most significant antibodies
(p values 3 x 10-16 to 1 x 10-9) are given in Table 4.
Discussion
In this randomized, crossover trial, we found that G&C supplementation statistically signifi-
cantly lowered mean serum CRP concentrations by 23% compared to placebo. In support of
this finding, “Cytokine activity” was the most significant pathway altered between the two in-
terventions in both the GO and KEGG gene-set enrichment analyses, and was lower after
G&C. Correspondingly, a number of individual cytokines and other inflammation-related fac-
tors were significantly lower in the proteomics panel, including several interleukins
and chemokines.
Our results are in agreement with a growing body of in vitro and animal research which sug-
gests that G&C have anti-inflammatory properties. Laboratory studies indicate that G&C in-
hibit NF-κB, by preventing the degradation of its inhibitory subunit, Iκ-B [10]. Thus, NF-κB is
unable to translocate to the nucleus, where this transcription factor activates the expression of
a battery of genes involved in inflammatory response and cell proliferation [32]. These anti-
inflammatory effects have been corroborated in vivo in animal studies. In rabbits with induced
atherosclerosis and chronic arthritis, treatment with G inhibited NF-κB activation and down-
regulated COX-2 expression in peripheral blood mononuclear cells, while also decreasing cir-
culating levels of CRP and IL-6 [33]. Further research has shown that mice fed a G-containing
diet for 56 days had lower serum IL-6 and TNFα than mice fed a control diet [34]. Two recent
Table 2. Inﬂammatory and oxidative stress biomarker concentrations after placebo and glucosamine and chondroitin intervention.
Biomarker Placebo (N = 18) Glucosamine & Chondroitin (N = 18) P
Mean (SD)1 Mean (SD)1
CRP (mg/l) 1.17 (0.17) 0.90 (0.13) 0.048
IL-6 (pg/ml) 0.89 (0.10) 0.81 (0.09) 0.27
sTNFRI (pg/ml) 871.3 (15.6) 901.6 (15.7) 0.17
sTNFRII (pg/ml) 5558 (103) 5633 (104) 0.34
PGE-M (ng/mg creatinine) 6.15 (0.41) 5.89 (0.39) 0.60
F2-isoprostane (ng/mg creatinine) 1.20 (0.08) 1.10 (0.08) 0.38
1Least squares geometric means (geometric SD) from GEE model adjusted for baseline values, age, sex, and body fat percent
doi:10.1371/journal.pone.0117534.t002
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Table 4. Top 100 (of 508) individual protein antibodies signiﬁcantly different after glucosamine and chondroitin supplementation versus placebo
intervention periods (n = 18).
Gene1 Function2 Effect
size3
P value*
CEACAM1 Cell-cell adhesion -2.45 8.7x10-15
SUZ12 Proliferation and histone methyltransferase activity [50,51] 1.09 1.7x10-14
THBS4 Cell-to-cell and cell-to-matrix interactions, extracellular mitogen -1.88 2.1x10-14
GADD45A Induced in response to DNA damage -1.37 2.8x10-14
ITGA5 Adhesion and cell-surface mediated signaling -1.54 9.7x10-14
ITGB4 Adhesion and cell-surface mediated signaling -1.89 1.2 x10-13
CSF3(GCSF)§ Cytokine involved in hematopoiesis and induction of granulocytes -3.06 2.1 x10-13
PKNOX1 RNA polymerase II distal enhancer 1.43 2.8 x10-13
IL13§ Immunoregulatory cytokine involved in inhibition of allergic reaction, particularly in the airways -6.29 3.5 x10-13
C1orf38 Mediates macrophage inﬂammatory response 3.67 4.6 x10-13
SON Splicing co-factor for cell-cycle progression and DNA-repair, involved in differentiation of hematopoietic
cells
1.02 6.4 x10-13
MUC3B Provides protective barrier against infectious agents at mucosal surfaces 3.83 1.3 x10-12
RUNX1 Subunit of transcription factor that binds to many enhancers and promoters, involved in development of
normal hematopoiesis
3.93 1.4 x10-12
IL17D Cytokine involved in the stimulation of other cytokines, e.g., IL6, IL8, and CSF -2.27 1.6 x10-12
BCAS2 Component of pre-mRNA splicesome complex 1.72 2.3 x10-12
KCNE3 Modulates gating kinetics of potassium voltage channel complexes 1.75 3.2 x10-12
CD44 Cell adhesion and migration, receptor for hyaluronic acid 1.50 3.3 x10-12
VEPH1 Function unknown 1.80 3.7 x10-12
HBEGF Normal heart function, smooth muscle cell proliferation, may be involved in macrophage mediated
proliferation
-1.47 5.2 x10-12
VCP Putative ATP-binding protein in vesicle transport and fusion, 26S proteasome function and assembly of
peroxisomes
-2.10 6.8 x10-12
COMP Structural integrity of cartilage, potent suppressor of apoptosis in chondrocytes -2.08 7.4 x10-12
IL8§ Chemokine, chemoattractant and potent angiogenic factor -2.35 9.9 x10-12
CAPN3 (NCL1) Intracellular protease, binds to titin -2.09 1.0 x10-11
GCM2 Transcription factor regulating parathyroid development 1.23 1.0 x10-11
PKC Regulation of cell growth and immune responses -0.89 1.3 x10-11
LASP1 Regulation of actin-based cytoskeletal activities -1.42 1.4 x10-11
SPP1
(Osteopontin)
Attachment of osteoclasts to the mineralized bone matrix; also a cytokine that upregulates expression of
interferon-gamma and interleukin-12
-6.45 1.7 x10-11
EFNB3 Ligand for Eph receptors involved in migration, repulsion and adhesion during neuronal, vascular and
epithelial development
-3.24 1.9 x10-11
HOXA4 Transcription factor that may regulate gene expression, morphogenesis and differentiation 1.88 2.3 x10-11
IL1β Cytokine involved in inﬂammatory response -2.65 2.3 x10-11
EGFR§ Cell proliferation 1.80 3.1 x10-11
PRKCQ Kinase involved in diverse cellular signaling pathways including T-cell activation, proliferation,
differentiation and survival
-1.68 3.1 x10-11
ENO1 Multifunctional glycolytic enzyme involved in glycolysis, growth control, hypoxia tolerance and allergic
response
-3.37 3.2 x10-11
SULF1 Inhibits signaling by heparin-dependent growth factors, diminishes proliferation and facilitates apoptosis 2.39 3.2 x10-11
MUC6 Modulates the composition of the protective mucus layer related to acid secretion or presence of bacteria
in the lumen
1.43 3.4 x10-11
HDA-1 Histone deacetylase; regulation of gene expression 1.35 4.3 x10-11
TACSTD2 Cell surface receptor that transduces calcium signals 1.20 4.9 x10-11
AXIN2 Inhibitor of Wnt signaling pathway, down-regulates beta-catenin 1.89 5.1 x10-11
(Continued)
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Table 4. (Continued)
Gene1 Function2 Effect
size3
P value*
IRS1 Mediates the control of various cellular processes by insulin -1.37 5.1 x10-11
VPS25 Formation and sorting of endosomal proteins destined for lysosomal degradation -1.26 5.6 x10-11
ANKRD11 Inhibits ligand-dependent activation of transcription 1.34 5.8 x10-11
DEFA1;A1B Antibacterial, fungicidal and antiviral activities -1.01 6.5 x10-11
RASGRF2 Signal coordination of mitogen-activated protein kinase pathways 1.07 8.3 x10-11
ESM1 Expressed in endothelial cells in lung and kidney, regulated by cytokines 3.77 8.5 x10-11
DSPP Dentinogenesis 2.18 8.6 x10-11
BAG1 Anti-apoptotic factor 1.52 9.3 x10-11
NOV Cell-adhesion, migration, proliferation, differentiation and survival -1.79 9.3 x10-11
LIFR§ Cytokine -4.54 1.2 x10-10
EXT2 Heparin sulfate bioysynthesis 1.16 1.2 x10-10
CXCL12(SDF1)§ Ligand for G-protein coupled receptor involved in inﬂammation -1.57 1.2 x10-10
CD55/DAF Regulation of the complement cascade 1.90 1.3 x10-10
LEF1 Involved in Wnt signaling and enhances T-cell receptor binding 2.58 1.4 x10-10
LIN28B Suppressor of microRNA biogenesis 1.40 1.4 x10-10
PRLR§ Cytokine receptor, interacts with prolactin 2.39 1.6 x10-10
MASP1 Complement activation -1.99 1.7 x10-10
KRT10 Cytoskeleton composition -1.56 1.8 x10-10
WAS Signal transducer for actin cytoskeleton 3.76 1.8 x10-10
FSCN1 Actin-bundling protein -1.48 2.0 x10-10
NAGLU Degrades heparin sulfate -1.85 2.1 x10-10
CCL20x Chemotactic factor 4.00 2.5 x10-10
MMP3 Extracellular matrix degradation 1.61 2.6 x10-10
DLAT Pyruvate dehydrogenase complex component which catalyzes the conversion of pyruvate to acetyl CoA -1.88 3.0 x10-10
SP1 Activator or repressor of transcription of a battery of genes related to cell growth, apoptosis, differentiation
and immune response
-1.46 3.0 x10-10
EREG Epidermal growth factor family member -4.04 3.0 x10-10
NOLA2 Ribosome biogenesis and telomere maintenance 3.92 3.1 x10-10
CALR3 Expressed in testis, may be required for sperm fertility -1.22 3.2 x10-10
IL4§ Cytokine produced by activated T cells -1.04 3.3 x10-10
ARHGEF17 Exchange factor for RhoA GTPases 1.86 3.3 x10-10
STMN1 (S15) Regulation of ﬁlament system destabilization 3.34 3.3 x10-10
SPARC
(Osteonectin)
Calciﬁcation of collagen in bone; also regulates cell shape and growth through interactions with
extracellular matrix and cytokines
-1.05 3.3 x10-10
FGR Negative regulator of cell migration and adhesion 1.60 3.5 x10-10
IL6§ Cytokine with diverse functions in inﬂammation, maturation of B cells, osteoblast formation, neuronal
differentiation, hematopoiesis and energy mobilization in muscle
1.33 3.8 x10-10
CCL5§ Chemoattractant for monocytes, memory T helper cells and eosinophils -2.78 4.4 x10-10
CSRP1 Cellular differentiation -1.11 4.9 x10-10
PEPD Recycling of proline, may be rate limiting for production of collagen -1.27 5.0 x10-10
LCK Key signaling molecule in selection and maturation of developing T-cells 1.22 5.2 x10-10
WNT3A Cell-cell signaling during embyogenesis -2.95 5.2 x10-10
DEPDC1 Transcriptional co-repressor 2.52 5.5 x10-10
KRT18 Uptake of thrombin-antithrombin complexes by hepatic cells; ﬁlament reorganization -1.56 5.5 x10-10
UBC Protein degradation -2.00 5.6 x10-10
SERPINB5 Tumor suppressor 1.27 6.1 x10-10
CCSP-2 Marker for colon cancer -1.69 6.1 x10-10
(Continued)
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studies reported that G&C administration has anti-inflammatory effects in the colon [35]. Bak,
et al [13], reported reduced TNFα, interleukin-1β, and NF-κB mRNA expression in colonic
mucosa in mice induced with colitis after supplementation of G at 0.10% diet (wet weight)
compared to control for four weeks. Finally, in rats with chemically-induced colitis, treatment
with G ameliorated symptoms of colitis, while decreasing both systemic and colonic inflamma-
tion, as measured by serum concentrations of IL-8 and amyloid P component, and colonic ex-
pression of NF-kB, IL-1β, and TNFα, respectively [35]. These studies are notable given our
findings of decreased colorectal cancer incidence with use of G&C in the VITAL study [4], and
significantly decreased concentrations of CEACAM1 (carcinoembryonic antigen-related cell
adhesion molecule 1) in the present study. CEACAM1 is an immunoglobulin involved in
cell-to-cell adhesion, and its overexpression is implicated in colorectal cancer [36]. Further,
this protein was the most significantly altered protein between the two interventions (effect
size-2.45; P = 8.7x10-15).
Despite the compelling results from in vitro and preclinical models, few studies have evalu-
ated the effects of G&C on inflammation in humans. In a nationally representative sample of
nearly 10,000 adults included the National Health and Nutrition Examination Study
(NHANES), regular use of G&C compared to nonuse was associated with a ~20% lower mean
concentrations of hsCRP [14]. In addition, we recently observed G&C use to be associated with
28–36% lower CRP concentrations, [37] and 40–47% lower oxidative stress, as measured by
urinary prostaglandin F2α (PGF2α) [38] among a sub-set of 220 individuals in the VITAL co-
hort [15]. Only two randomized trials of G &/or C on markers of inflammation have been con-
ducted. In a small trial, 36 osteoarthritis patients were given 1500 mg G and 675 mg C for
Table 4. (Continued)
Gene1 Function2 Effect
size3
P value*
EGR1 Activates transcription of genes required for mitogenesis and differentiation 1.36 6.3 x10-10
DCN Matrix assembly 1.85 6.4 x10-10
TNFRSF9§ TNF receptor family -3.59 6.9 x10-10
CD142(F3) Initiates blood coagulation -1.29 7.3 x10-10
NPEPL1 Aminopeptidase activity 2.01 7.4 x10-10
KPNA2 Nuclear transport of proteins 2.01 7.7 x10-10
BRCA1 Tumor suppressor 2.08 7.7 x10-10
IER3 Anti-apoptotic factor 2.56 7.8 x10-10
PHLDA2 Tumor Suppressor -2.73 8.2 x10-10
AK1 Cellular energy homeostasis and adenine nucleotide metabolism 2.40 8.5 x10-10
F13B Coagulation factor -3.38 8.5 x10-10
GJA1 (pS373) Gap junction protein 1.99 8.8 x10-10
STX11 Protein transport 1.22 9.3 x10-10
TLN1/TLN2 Cytoskeletal protein -1.64 9.3 x10-10
PPP2CA Negative control of cell-growth and division -2.08 9.4 x10-10
FUT8 Catalyzes addition of fucose in alpha 1–6 linkages 2.36 1.0 x10-09
ITGA1 Adhesion and cell-surface mediated signaling -1.94 1.0 x10-09
CNOT7 Negative regulator of cell proliferation -1.34 1.1 x10-09
1Indicates that protein was in the GO (Gene Ontology) or KEGG (Kyoto Encyclopedia of Genes and Genomes) Cytokines pathway
2Information pertaining to function is derived from PubMed Gene and/or UniProtKB unless otherwise noted
3Values >1 indicate greater antibody expression after supplementation with G&C compared to placebo; values <1 indicate lower expression
*All proteins listed were statistically signiﬁcant with Bonferroni correction (P <1.70x10-5)
doi:10.1371/journal.pone.0117534.t004
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twelve weeks [39]. A significant reduction in serum PGE2 was observed among the G&C treat-
ed group, with post-treatment levels similar to that of 25 age-matched healthy controls. The
same group conducted a second trial in which 51 rheumatoid arthritis patients were random-
ized to receive either 1500 mg G or placebo for twelve weeks [40]. While treatment with G re-
duced serumMMP-3 levels, CRP concentrations remained unchanged. However, exposure
was limited to G alone (without C) and patients continued taking regular medications through-
out the study. Furthermore, as individuals with rheumatoid arthritis have higher levels of in-
flammation than the general population, the results of this study may not be generalizable to a
healthy population.
Additional inflammation-related pathways that were significantly different between inter-
ventions with Bonferroni correction included JAK/STAT signaling, a signaling pathway for a
broad range of cytokines and growth factors [41]; intestinal immune network for IgA produc-
tion, which serves as the first line of defense against microorganisms in the intestinal mucosa
[42]; leukocyte transendothelial migration, the movement of leukocytes from blood into tissues
for immune surveillance and inflammation [43]; and hematopoietin/interferon cytokine recep-
tor binding, which includes class I cytokines, mainly the interleukins, and growth factors.
G-protein coupled receptors are involved in diverse biologic functions, but include roles in
growth and regulation of inflammation [44]. As with the cytokine pathway, the majority of
the probes in these pathways were less abundant after G&C as compared to placebo. In fact,
of the 30 significant pathways, the majority of probes were less abundant in all but two
pathways—ubiquitin-mediated proteolysis and proteins contained in the nucleus. Alterations
in these other inflammation-related pathways suggest that G&C may have wider-ranging ef-
fects on inflammation beyond inhibition of transcription factor NF-kB.
Significant differences in other pathways between the interventions indicate that G&C may
play a role in other biologic functions that have not been previously associated with this supple-
ment. For example, pathways related to microtubule function, regulation of actin polymeriza-
tion, filament length, cytoskeleton organization, and locomotory activity were lower after
G&C. Although there is overlap among some genes representing the pathways, these differ-
ences suggest that G&C may have effects on cell division and motility, targets of a growing
number of chemotherapeutic drugs [45–47]. Lower protein concentrations in pathways related
to external and biotic stimulus, and other organisms were likely related to reduction in
inflammation-related signaling, particularly given the antibodies contained on our assay.
Other pathways that differed between the interventions were based on cellular component or
location. The meaning of these differences in unrelated proteins, in terms of health conse-
quences, is unclear.
Among the most significant individual proteins that were differentially abundant between
the interventions in the proteomics analysis, several in the top ten were related to cell-adhesion
(CEACAM, THBS4, ITGA and B). Other proteins with large effect sizes were IL-13 (down;
-6.29), an immunoregulatory cytokine involved in inhibition of allergic reaction, particularly
in the airways; osteopontin (down; -6.45), which is involved in the attachment of osteoclasts
to the mineralized bone matrix, and is also a cytokine that upregulates the expression of
interferon-gamma and IL-12; and C1orf38 (up; 3.67), involved in mediating macrophage in-
flammatory response. Consistent with the lower CRP concentrations measured in serum, CRP
was also down-regulated in plasma on the antibody array (down; -0.5, P = 0.001) but was not
significant with correction for multiple testing. As has been observed in many other serum/
plasma studies [48,49], some of the proteins with significant changes are normally cytoplasmic
or nuclear, so their role as putative serum/plasma biomarkers is unclear. They could indicate
sufficient apoptosis and/or necrosis of cells to be detectable and imply that this is reduced with
G&C treatment.
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This is the first randomized trial to evaluate the effects of G&C on inflammation in healthy
adults, and the first to assess potential pathways perturbed by G&C using a broad proteomic
screen and gene set enrichment analyses. A major strength of this study is that participants
were healthy and free of underlying inflammatory conditions, and the stringent inclusion and
exclusion criteria minimized effects of other factors that may affect inflammatory status, (e.-
g., age, tobacco or medication use, chronic health conditions). Despite the small sample size,
many of the intervention effects in the proteomics pathway analyses and for individual proteins
were highly significant, exceeding by orders of magnitude, the Bonferroni corrections and the
effects observed in multiple previous analyses we have performed in which we compared plas-
ma samples in cancer cases and controls [23,26,27]. Detection of these highly significant effects
appears to be due to our use of the randomized, crossover, placebo-controlled design where
each participant acted as his or her own control. A strength of the platform is the significant
coverage of the proteome including many cytokines (~3,000 proteins). Thus, it is a powerful
approach for identifying pathways that change in response to an intervention. Furthermore, it
is a powerful discovery method for identifying individual biomarkers that may play an impor-
tant role in the process being studied. Individual protein results warrant validation by other
means such as ELISA or immunoblot since the array uses only a single antibody to bind the
protein from plasma and the indicated antibody could bind a protein in plasma that is not the
one claimed by the manufacturer (i.e., the specificity of each antibody has not be determined).
Finally, given the sample size of the current study, the anti-inflammatory properties of G&C
need to be replicated in larger randomized trials and should evaluate sex-specific effects.
In summary, we found that G&C significantly reduced circulating CRP concentrations com-
pared to placebo, and gene set enrichment analyses indicated that cytokine activity and other
inflammation-related pathways were significantly decreased. These results are supported by in
vitro and animal studies demonstrating anti-inflammatory properties of G&C, as well as
human observational data which show an association between G&C use and lower concentra-
tions of circulating CRP. Thus, there is now growing evidence that G&C reduce systemic in-
flammation in humans. This evidence may also provide a possible biologic mechanism to
support prior findings that use of G&C supplements is associated with reduced lung and colon
cancer and overall mortality. Future studies in larger samples and other populations are needed
to determine the potential utility of G&C as a possible anti-inflammatory agent.
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